Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Impact of 0.05% cyclosporine A on visual quality in patients with Post-refractive surgery dry eye.
Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo investigate the effects of 0.05% Cyclosporine A (CsA) eye drops on visual quality including corneal higher-order aberrations (HOAs) in post-refractive surgery dry eye syndrome (DES) patients.
methodsThis prospective, randomized study involves 52 patients diagnosed with post-refractive surgery DES. The control group (22 eyes) received conventional dry eye therapy (20% deproteinized calf serum, 3% diquafosol tetrasodium eye drops), and the treatment group (30 eyes) received an additional 0.05% CsA. Corneal HOAs, corneal fluorescein staining (CFS), tear break-up time (TBUT), tear meniscus height (TMH), redness index, meibography, Ocular Surface Disease Index (OSDI), and subjective visual quality scores were assessed before and after three months.
resultsBoth groups showed significant improvements (with no significant differences between groups) in TBUT, redness index, and ODSI. Compared with the control group, corneal HOAs, visual quality subjective scores, and CFS scores improved significantly in the treatment group. For the treatment group, Z(3, 1) and Z(4, -2) over 3 mm zone as well as Z(3, 1), Z(4, -2) and Z(4, -4) term over 5 mm zone showed significant changes after three months of treatment.
conclusionThe administration of 0.05% CsA significantly improved tear film stability and reduced corneal HOAs, enhancing visual quality in post-refractive surgery DES patients. KEY MESSAGES: What is known Post-refractive surgery dry eye syndrome (DES) can degrade visual quality due to increased higher-order aberrations (HOAs) and tear film instability. Cyclosporine A (CsA) 0.05% has recognized anti-inflammatory effects and is commonly used to manage various types of DES. What is new The addition of 0.05% CsA to conventional DES treatment significantly improves corneal HOAs and subjective visual quality in post-refractive surgery patients. This study provides quantitative evidence that CsA not only relieves post-refractive DES symptoms but also enhances visual performance through improved tear film stability and optical quality.
Indexed as
Identifiers
41212221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.